Do you want to read an article? Please log in or register.
Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success
Macular Diseases
Related content
Macular Diseases
AFLIBERCEPT FOR PERSISTENT DIABETIC MACULAR EDEMA: Forty-Eight-Week Outcomes
Retina.
Bahrami B, Hong T, Schlub TE, Chang AA
doi: 10.1097/IAE.
Macular Diseases
Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial
JAMA Ophthalmol.
Bressler NM, Beaulieu WT, Glassman AR, Blinder KJ, Bressler SB, Jampol LM, Melia M, Wells JA 3rd; Diabetic Retinopathy Clinical Research Network
doi: 10.1001/
COMMENTED
Macular Diseases
Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study)
doi: 10.1016/j.ophtha.2020.03.021.
Macular DiseasesRetinal Diseases
PREDICTORS OF REFRACTORY MACULAR EDEMA AFTER BRANCH RETINAL VEIN OCCLUSION FOLLOWING INTRAVITREAL BEVACIZUMAB
Retina.
Moon BG, Cho AR, Kim YN, Kim JG
doi: 10.1097/IAE.
COMMENTED
Macular Diseases
Association Between Change in Visual Acuity and Change in Central Subfield Thickness During Treatment of Diabetic Macular Edema in Participants Randomized to Aflibercept, Bevacizumab, or Ranibizumab: A Post Hoc Analysis of the Protocol T Randomized Clinical Trial
JAMA Ophthalmol.
Bressler NM, Odia I, Maguire M, Glassman AR, Jampol LM, MacCumber MW, Shah C, Rosberger D, Sun JK, DRCR Retina Network.
doi: 10.1001/jamaophthalmol.
Macular Diseases
Month 12 Outcomes After Treatment Change at Month 6 Among Poor Responders to Aflibercept or Bevacizumab in Eyes with Macular Edema Secondary to Central or Hemiretinal Vein Occlusion: A Secondary Analysis of the SCORE2 Study
JAMA Ophthalmol.
Ip MS, Oden NL, Scott IU, VanVeldhuisen PC, Blodi BA, Ghuman T, Baker CW; SCORE2 Investigator Group
doi: 10.1001/jamaophthalmol.
Macular Diseases
Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T
Curr Opin Ophthalmol.
Cai S, Bressler NM
doi: 10.1097/
RECOMMENDED
Macular Diseases
Ranibizumab or Aflibercept for Diabetic Macular Edema: Comparison of 1-Year Outcomes from the Fight Retinal Blindness! Registry
★ 3
Recommended by
Prof. Dr Daniel Barthelmes, Faculty Member
★ 3
Recommended by
Prof. Dr Ke Yao, Faculty Member
Ophthalmology.
Bhandari S, Nguyen V, Fraser-Bell S, Mehta H, Viola F, Baudin F, Gabrielle PH, Creuzot-Garcher C, Gillies M, Barthelmes D
doi: 10.1016/j.ophtha.2019.11.018.
COMMENTED
Macular Diseases
Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion: A Randomized Clinical Trial
JAMA Ophthalmol.
Hykin P, Prevost AT, Vasconcelos JC, Murphy C, Kelly J, Ramu J, Hounsome B, Yang Y, Harding SP, Lotery A, Chakravarthy U, Sivaprasad S, LEAVO Study Group.
doi: 10.1001/